
How Brain-Computer Interfaces Are Mapping the Future of Neurotechnology
In this episode of MedDevice by Design, we explore the world of brain-computer interfaces (BCIs) and the challenges of capturing thought into action. Mark Drlik and Ariana Wilson walk through how these systems translate brain activity into control signals for devices—without needing surgical implants.
What Is a Brain-Computer Interface?
A brain-computer interface captures electrical signals in the brain and maps them to physical or digital actions. Many BCIs use EEG (electroencephalography) to read brain activity from outside the skull and convert patterns into commands. These signals are then interpreted in real time to drive assistive technologies or interact with digital systems.
Key Technical and Ethical Challenges
One challenge is signal noise—especially for non-invasive EEG systems that must read through the skull. Another is user variability, since everyone’s brain activity is slightly different. Ethical concerns around data privacy are significant, as BCIs collect sensitive neurological data. Processing speed is also an issue: the brain fires up to 100 million action potentials per second, at speeds reaching 120 meters per second.
How BCIs Are Being Used
Current BCI applications include neurorehabilitation for people with paralysis or ALS, and emerging uses in gaming and virtual reality. Companies like Neuralink are exploring implanted interfaces, while open-source projects like OpenBCI and institutions like MIT and Stanford lead the research front.
Enjoying MedDevice by Design? Sign up to get new episodes sent to your inbox.
Related Resources

Your team is ready for design validation. The prototype performs well, test plans are in motion, and everything points to a smooth handoff to manufacturing. Then your partner calls with bad news: they can’t build the device as designed.

You’ve cleared the toughest engineering hurdles and proven your design works. Then, just as you prepare to scale, your contract manufacturer turns you down.

In Medtech, a successful exit isn’t just about having an innovative device, it’s about building a business that potential buyers and investors can clearly see a future in.

Being ready to build is not the same as being ready to scale. Successful market introduction requires manufacturing readiness that evolves alongside market readiness.